definium therapeutics reports promising phase iii results for LSD‑based depression drug

At a glance:

• Primary data from a phase III trial of Definium Therapeutics' LSD‑derived drug DT120 showed an 8.1‑point greater drop on a standard depression scale versus placebo.
• The double‑blind study enrolled 149 participants across 20 sites; a single 100 µg dose produced a 35% response rate by week 6 and a 12% remission rate.
• Definium plans to seek FDA breakthrough‑therapy designation and expedited approval for DT120.

Trial results and statistical highlights

Definium Therapeutics released primary data on Monday from its phase III “Emerge” trial of DT120, a proprietary lysergic acid diethylamide (LSD) formulation. The study randomized 149 adults diagnosed with major depressive disorder at 20 clinical sites to receive either a single 100‑microgram oral dose of DT120 or a matching placebo. Participants were followed for 12 weeks in a double‑blind fashion.

By the six‑week assessment, patients receiving DT120 exhibited an average 8.1‑point larger reduction on the widely used depression rating scale compared with the placebo group. Moreover, 35 % of DT120 recipients achieved a ≥50 % symptom reduction (defined as a “substantial response”), versus only 7 % of placebo participants. Remission—no longer meeting criteria for active depression—was observed in 12 % of the DT120 arm compared with 3 % of placebo. Although the magnitude of benefit tapered slightly, the treatment effect remained statistically significant at the 12‑week mark.

What DT120 is and how it works

LSD, short for lysergic acid diethylamide, is a semisynthetic compound derived from the ergot fungus. Traditionally known for its psychedelic and hallucinogenic properties, recent research suggests that LSD can promote rapid neuroplasticity—forming new neural connections that may alleviate depressive symptoms. Definium’s DT120 is formulated as an oral tablet intended for a single‑dose administration, with psychoactive effects lasting 6–12 hours depending on dose. The company hopes that this one‑time treatment can provide rapid and durable relief, sidestepping the chronic daily dosing required by most antidepressants.

Regulatory pathway and next steps

Definium, formerly MindMed, said it will request breakthrough‑therapy designation (BTD) from the U.S. Food and Drug Administration. BTD is intended to accelerate the review of drugs that show substantial improvement over existing therapies for serious conditions. The agency typically requires two positive, well‑controlled phase III trials before granting approval. Definium is already running a second double‑blind, placebo‑controlled phase III study of DT120, codenamed Ascend, and expects primary results later this year. Both the Emerge and Ascend trials include open‑label extension phases, allowing participants to receive DT120 based on symptom severity after the blinded period.

Broader context of psychedelic medicine

The Emerge trial represents one of the largest investigations of LSD as a therapeutic agent for depression. While LSD has a long history as a recreational substance, the past decade has seen a resurgence of scientific interest in classic psychedelics—including psilocybin and ayahuasca—for a range of psychiatric disorders. Early‑phase studies have hinted at rapid symptom relief and sustained benefits, but large, rigorously controlled trials like Definium’s are essential to move the field from anecdote to approved medication. If DT120 ultimately secures FDA approval, it could become a practice‑changing option for patients who have not responded to conventional antidepressants, potentially reducing the need for daily medication adjustments and associated side effects.

Outlook for patients and providers

According to lead trial researcher John Sonnenberg, a clinical psychologist at Northwestern University Feinberg School of Medicine, the data suggest “unprecedented and highly differentiated efficacy” that could reshape treatment algorithms. For clinicians, a single‑dose, rapid‑acting therapy may simplify prescribing workflows and improve adherence. For patients, especially those experiencing partial responses or intolerable side effects from existing drugs, DT120 could offer a fundamentally different therapeutic pathway. The company is also expanding the DT120 program to generalized anxiety disorder, with phase III results anticipated later in the year.